[Chilean experience with the use of 18F-deoxyglucose positron emission tomography]

Rev Med Chil. 2007 Mar;135(3):375-83. doi: 10.4067/s0034-98872007000300014. Epub 2007 Apr 26.
[Article in Spanish]

Abstract

Background: Clinical oncology is the main application of 18F-deoxyglucose (FDG) positron emission tomography (PET).

Aim: To evaluate the first 1,000 patients studied with FDG PET in Chile.

Material and methods: Retrospective analysis of 1,000 patients (aged between 1 and 94 years, 550 females) studied with FDG PET, since 2003. All studies were performed in a high resolution Siemens Ecat-Exact HR (+). All reports were based on the visual analysis of three plane and three-dimensional images.

Results: Ninety seven percent of exams were done for oncological indications, mainly lung lesions, lymphoma, colorectal and gastroesophageal, cancer and breast tumors. Only 1% of patients had brain tumors. Non tumor neurological indications corresponded to 1.7%. Cardiac studies were only 0.3% and inflammatory process corresponded to 1%. The 5.6% corresponded to pediatric population. Six percent of patients were aged less than 18 years and in 50% of them, the indication was oncological, mainly lymphomas, brain tumors, endocrine cancers and sarcomas. The remaining 50% had a neurological indications, mainly for refractory epilepsy.

Conclusions: PET FDG imaging was effective in the management of diverse diseases of children and adults.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Child
  • Child, Preschool
  • Chile
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Neoplasms / diagnostic imaging*
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Retrospective Studies

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18